Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{737a3b43b9b14fb6af0d7589df27d2db,
title = "Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation",
abstract = "OBJECTIVES: Vitamin E has antioxidant and immunomodulatory effects that might influence the development of acute graft-versus-host disease (GvHD). We investigated the association between plasma vitamin E levels and acute GvHD.METHODS: We studied 115 adults who underwent myeloablative allogeneic hematopoietic cell transplantation between July 2015 and August 2018. Vitamin E was measured by high-performance liquid chromatography in stored plasma samples obtained pre-transplantation at day -23 (±15 days) and post-transplantation at day +28 (±3 days).RESULTS: Pre-transplantation vitamin E levels were inversely associated with grade II-IV acute GvHD (hazard ratio 0.68 per 10 µmol/L increase, 95% confidence interval [CI]: 0.47-0.98). The association remained after adjustment for known prognostic factors for acute GvHD. Patients with levels below the median had a cumulative incidence of grade II-IV acute GvHD of 46% (CI: 33-59%) versus 21% (CI: 10-32%) in patients with levels above the median. No clear association with non-relapse mortality, relapse, or chronic GvHD was found. Post-transplantation vitamin E levels (measured in 72 [63%] patients) were correlated with pre-transplantation levels (ρ = .31) but were not associated with subsequent grade II-IV acute GvHD.CONCLUSIONS: High pre-transplantation vitamin E levels were associated with less acute GvHD.",
keywords = "acute graft&#8208, versus&#8208, host disease, allogeneic hematopoietic cell transplantation, vitamin E, acute graft-versus-host disease",
author = "Gjaerde, {Lars Klingen} and Ostrowski, {Sisse Rye} and Lia Minculescu and Andersen, {Niels Smedegaard} and Friis, {Lone Smidstrup} and Brian Kornblit and Petersen, {S{\o}ren Lykke} and Ida Schj{\o}dt and Henrik Sengel{\o}v",
note = "{\textcopyright} 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2021",
month = mar,
doi = "10.1111/ejh.13567",
language = "English",
volume = "106",
pages = "417--424",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell Munksgaard",
number = "3",

}

RIS

TY - JOUR

T1 - Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation

AU - Gjaerde, Lars Klingen

AU - Ostrowski, Sisse Rye

AU - Minculescu, Lia

AU - Andersen, Niels Smedegaard

AU - Friis, Lone Smidstrup

AU - Kornblit, Brian

AU - Petersen, Søren Lykke

AU - Schjødt, Ida

AU - Sengeløv, Henrik

N1 - © 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2021/3

Y1 - 2021/3

N2 - OBJECTIVES: Vitamin E has antioxidant and immunomodulatory effects that might influence the development of acute graft-versus-host disease (GvHD). We investigated the association between plasma vitamin E levels and acute GvHD.METHODS: We studied 115 adults who underwent myeloablative allogeneic hematopoietic cell transplantation between July 2015 and August 2018. Vitamin E was measured by high-performance liquid chromatography in stored plasma samples obtained pre-transplantation at day -23 (±15 days) and post-transplantation at day +28 (±3 days).RESULTS: Pre-transplantation vitamin E levels were inversely associated with grade II-IV acute GvHD (hazard ratio 0.68 per 10 µmol/L increase, 95% confidence interval [CI]: 0.47-0.98). The association remained after adjustment for known prognostic factors for acute GvHD. Patients with levels below the median had a cumulative incidence of grade II-IV acute GvHD of 46% (CI: 33-59%) versus 21% (CI: 10-32%) in patients with levels above the median. No clear association with non-relapse mortality, relapse, or chronic GvHD was found. Post-transplantation vitamin E levels (measured in 72 [63%] patients) were correlated with pre-transplantation levels (ρ = .31) but were not associated with subsequent grade II-IV acute GvHD.CONCLUSIONS: High pre-transplantation vitamin E levels were associated with less acute GvHD.

AB - OBJECTIVES: Vitamin E has antioxidant and immunomodulatory effects that might influence the development of acute graft-versus-host disease (GvHD). We investigated the association between plasma vitamin E levels and acute GvHD.METHODS: We studied 115 adults who underwent myeloablative allogeneic hematopoietic cell transplantation between July 2015 and August 2018. Vitamin E was measured by high-performance liquid chromatography in stored plasma samples obtained pre-transplantation at day -23 (±15 days) and post-transplantation at day +28 (±3 days).RESULTS: Pre-transplantation vitamin E levels were inversely associated with grade II-IV acute GvHD (hazard ratio 0.68 per 10 µmol/L increase, 95% confidence interval [CI]: 0.47-0.98). The association remained after adjustment for known prognostic factors for acute GvHD. Patients with levels below the median had a cumulative incidence of grade II-IV acute GvHD of 46% (CI: 33-59%) versus 21% (CI: 10-32%) in patients with levels above the median. No clear association with non-relapse mortality, relapse, or chronic GvHD was found. Post-transplantation vitamin E levels (measured in 72 [63%] patients) were correlated with pre-transplantation levels (ρ = .31) but were not associated with subsequent grade II-IV acute GvHD.CONCLUSIONS: High pre-transplantation vitamin E levels were associated with less acute GvHD.

KW - acute graft&#8208

KW - versus&#8208

KW - host disease

KW - allogeneic hematopoietic cell transplantation

KW - vitamin E

KW - acute graft-versus-host disease

UR - http://www.scopus.com/inward/record.url?scp=85097780766&partnerID=8YFLogxK

U2 - 10.1111/ejh.13567

DO - 10.1111/ejh.13567

M3 - Journal article

C2 - 33314420

VL - 106

SP - 417

EP - 424

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 3

ER -

ID: 61698703